Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-C008: Disitamab Vedotin in HER2+ Gastric Cancer
NCT03556345Phase 2Completed
- Sponsor
- RemeGen
- Start
- Jul 2018
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in gastric cancer (GC), sponsored by RemeGen. Started Jul 2018; status: completed.
02
Drugs
disitamab vedotin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03556345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03556345.